Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Short Interest Update

Enlivex Therapeutics Ltd. (NASDAQ:ENLVGet Free Report) saw a large decrease in short interest in the month of April. As of April 30th, there was short interest totalling 263,200 shares, a decrease of 5.6% from the April 15th total of 278,700 shares. Based on an average daily volume of 178,100 shares, the days-to-cover ratio is presently 1.5 days.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and set a $7.00 price objective on shares of Enlivex Therapeutics in a report on Tuesday, April 23rd.

Get Our Latest Research Report on Enlivex Therapeutics

Enlivex Therapeutics Price Performance

Shares of ENLV stock opened at $1.40 on Friday. Enlivex Therapeutics has a fifty-two week low of $1.15 and a fifty-two week high of $4.59. The firm’s 50 day moving average price is $2.64 and its two-hundred day moving average price is $2.54.

Enlivex Therapeutics (NASDAQ:ENLVGet Free Report) last announced its quarterly earnings results on Friday, March 29th. The company reported ($0.48) earnings per share (EPS) for the quarter. Analysts expect that Enlivex Therapeutics will post -0.86 EPS for the current year.

Enlivex Therapeutics Company Profile

(Get Free Report)

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors.

Further Reading

Receive News & Ratings for Enlivex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enlivex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.